Kymab is discovering and developing fully human monoclonal antibody therapeutics using our pioneering Kymouse™ platform. We are building a rich pipeline of assets in four therapeutic spaces: immuno-oncology, inflammation, haematology and infectious diseases.

The Kymouse strains have more base-pairs of the human immunoglobulin genes than any other model. Their performance is exceptional: virtually every mouse responds to challenge, producing high-titre polyclonal antibodies to a variety of antigens including highly conserved human antigens.

Company growth
Type
Private
HQ
Cambridge, CB22 3AT, GB
Founded
2009
Size (employees)
101 (est)+1%
Kymab was founded in 2009 and is headquartered in Cambridge, CB22 3AT, GB

Kymab Office Locations

Kymab has office in Cambridge, CB22 3AT
Cambridge, CB22 3AT, GB

Kymab Metrics

Kymab Summary

Founding Date

2009

Total Funding

$220 M

Latest funding size

$100 M

Time since last funding

3 months

Investors

We estimate that Kymab's latest funding round in November 2016 was $100 M. In total, Kymab has raised $220 M

Market Position – drug development, Technology, healthtech, biotech, Health, medical devices

Kymab Company Life

You may also be interested in